OncoMatch/Clinical Trials/NCT06162377
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.
Is NCT06162377 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Methylnaltrexone for head and neck squamous cell carcinoma.
Treatment: Methylnaltrexone — To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Lab requirements
Kidney function
chronic kidney disease defined as a eGRF <60 ml/mim [excluded]
Liver function
liver disease defined as transaminitis > 2 folds from normal levels, cirrhosis and hyperbilirubinemia > 2 folds from normal levels [excluded]
Participants with uncontrolled intercurrent illness, including chronic kidney disease defined as a eGRF <60 ml/mim, and liver disease defined as transaminitis > 2 folds from normal levels, cirrhosis and hyperbilirubinemia > 2 folds from normal levels
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06162377 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages